https://crstodayeurope.com/news/formycon-receives-approval-in-the-uk-for-eylea-biosimilar/2482680/daily0.7https://crstodayeurope.com/news/mount-sinai-team-identifies-underlying-mechanisms-of-age-related-meibomian-gland-dysfunction-possible-treatment-for-dry-eye-disease/2482679/daily0.7https://crstodayeurope.com/news/alcon-announces-us-launch-of-systane-pro-pf-for-dry-eye-relief/2482678/daily0.7https://crstodayeurope.com/news/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa/2482677/daily0.7https://crstodayeurope.com/news/myeyedr-partners-with-cofi-to-streamline-patient-payments/2482673/daily0.7https://crstodayeurope.com/news/seonix-bio-launches-sightscore-the-first-clinical-polygenic-risk-score-test-for-glaucoma-in-the-us/2482672/daily0.7https://crstodayeurope.com/news/cost-purchase-factors-and-correct-usage-drive-online-contact-lens-searches-according-to-new-research-in-the-us-and-canada/2482671/daily0.7https://crstodayeurope.com/news/oculus-launches-myopia-software-package-on-the-pentacam-axl-wave/2482670/daily0.7https://crstodayeurope.com/news/alcon-announces-us-launch-of-voyager-dslt-for-glaucoma-and-ocular-hypertension/2482669/daily0.7https://crstodayeurope.com/news/fda-clears-new-world-medicals-via360-surgical-system/2482667/daily0.7https://crstodayeurope.com/news/reports-new-round-of-layoffs-at-fda-and-cdc/2482666/daily0.7https://crstodayeurope.com/news/fred-moll-founder-of-intuitive-surgical-joins-forsight-robotics-board-of-directors/2482664/daily0.7https://crstodayeurope.com/news/virtual-vision-health-launches-visual-acuity-testing-on-virtual-eye-vr-platform/2482663/daily0.7https://crstodayeurope.com/news/kala-bio-announces-chief-executive-officer-transition/2482662/daily0.7https://crstodayeurope.com/news/call-for-nominations-prevent-blindness-seeks-to-honor-leaders-in-vision-health/2482661/daily0.7https://crstodayeurope.com/news/aao-responds-to-proposed-cuts-to-nih-research-payments/2482660/daily0.7https://crstodayeurope.com/news/essilorluxottica-acquires-canadian-med-tech-start-up-cellview/2482659/daily0.7https://crstodayeurope.com/news/teclens-secures-93-million-series-a-funding-to-advance-its-noninvasive-refractive-technology/2482658/daily0.7https://crstodayeurope.com/news/digitaloptometrics-to-preview-worlds-first-autonomous-slitlamp-at-vision-expo-east-2025/2482655/daily0.7https://crstodayeurope.com/news/bausch-lomb-no-immediate-plans-to-go-private/2482653/daily0.7https://crstodayeurope.com/news/lumenis-launces-optilift-device-to-address-lower-lid-laxity-and-impaired-blinking/2482652/daily0.7https://crstodayeurope.com/news/cofi-reaches-new-milestone-10000-vision-providers-are-now-active-on-cofis-multi-party-payment-platform/2482648/daily0.7https://crstodayeurope.com/news/qlaris-bio-announces-positive-topline-data-from-two-phase-2-trials-of-qls-111-for-glaucoma/2482647/daily0.7https://crstodayeurope.com/news/fda-approves-susvimo-for-diabetic-macular-edema-dme/2482646/daily0.7https://crstodayeurope.com/news/mckesson-acquires-controlling-interest-in-prism-vision-holdings/2482645/daily0.7https://crstodayeurope.com/news/iantrek-appoints-adam-szaronos-as-chief-executive-officer/2482644/daily0.7https://crstodayeurope.com/news/multifocal-contact-lens-in-children-slows-myopia-progression-with-lasting-effects-nih-study/2482643/daily0.7https://crstodayeurope.com/news/rayner-completes-recruitment-for-rayone-galaxy-ide-study/2482642/daily0.7https://crstodayeurope.com/news/iantrek-announces-first-commercial-cases-of-crex-micro-interventional-system-for-trabecular-outflow-enhancement/2482640/daily0.7https://crstodayeurope.com/news/bvi-medical-launches-educational-platform-for-ophthalmology-professionals/2482639/daily0.7https://crstodayeurope.com/news/surgilums-robomarker-g2-receives-5-international-medical-device-design-awards/2482638/daily0.7https://crstodayeurope.com/news/harrow-partners-with-cencora-to-launch-harrow-cares-program/2482637/daily0.7https://crstodayeurope.com/news/applications-being-accepted-for-the-new-aaof-and-meta-reality-labs-research-15-million-open-science-myopia-grant/2482636/daily0.7https://crstodayeurope.com/news/norlase-receives-fda-510k-clearance-and-ce-mark-for-lynx-pattern-scanning-laser-indirect-ophthalmoscope/2482634/daily0.7https://crstodayeurope.com/news/coopervision-names-steven-robins-as-president-americas/2482633/daily0.7https://crstodayeurope.com/news/hoya-vision-care-expands-miyosmart-power-range-for-high-myopia-treatment-in-children/2482630/daily0.7https://crstodayeurope.com/news/merit-acquires-osod-to-expand-ophthalmic-drug-development-services/2482629/daily0.7https://crstodayeurope.com/news/heidelberg-hosts-first-international-glaucoma-symposium/2482628/daily0.7https://crstodayeurope.com/news/pantheon-vision-advances-corneal-implant-development/2482627/daily0.7https://crstodayeurope.com/news/rayone-emv-toric-iol-approved-by-health-canada/2482626/daily0.7https://crstodayeurope.com/news/helpmesee-expands-simulation-based-cataract-surgery-training-with-new-partnerships-at-usc-and-uic/2482623/daily0.7https://crstodayeurope.com/news/prevent-blindness-receives-legacy-donation-97-million-largest-in-history/2482622/daily0.7https://crstodayeurope.com/news/rayner-announces-full-commercial-launch-of-rayone-galaxy-and-rayone-galaxy-toric/2482617/daily0.7https://crstodayeurope.com/news/specialty-contact-lens-division-wave-eye-care-formed/2482616/daily0.7https://crstodayeurope.com/news/sling-therapeutics-announces-positive-topline-results-from-phase-2b3-lids-trial-of-oral-small-molecule-linsitinib-in-patients-with-ted/2482614/daily0.7https://crstodayeurope.com/news/tangible-science-announces-ceo-transition/2482613/daily0.7https://crstodayeurope.com/news/bausch-lomb-makes-two-deals-to-bolster-therapeutic-pipeline-in-ga-and-glaucoma/2482612/daily0.7https://crstodayeurope.com/news/fda-approves-zeiss-mel-90-excimer-laser/2482611/daily0.7https://crstodayeurope.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols-in-the-european-union/2482610/daily0.7https://crstodayeurope.com/news/tenpoint-therapeutics-announces-positive-topline-data-from-phase-3-pivotal-study-of-brimochol-pf-for-the-treatment-of-presbyopia/2482609/daily0.7https://crstodayeurope.com/news/fda-clears-epithelial-thickness-module-for-heidelberg-engineerings-anterion-multidisciplinary-imaging-platform/2482607/daily0.7https://crstodayeurope.com/news/altris-ai-introduces-ai-powered-fluid-and-ga-quantification-features/2482606/daily0.7https://crstodayeurope.com/news/dry-eye-institute-launches-dei-on-demand-and-kicks-off-inaugural-road-event/2482605/daily0.7https://crstodayeurope.com/news/rayner-introduces-redesigned-raytrace-for-quicker-and-clearer-iol-calculations/2482604/daily0.7https://crstodayeurope.com/news/aviceda-therapeutics-raises-2075-million-to-advance-lead-program-avd-104-for-geographic-atrophy-into-phase-3-testing/2482603/daily0.7https://crstodayeurope.com/news/canyon-labs-acquires-iuvo-biosciences-lab-services-and-consulting-businesses/2482600/daily0.7https://crstodayeurope.com/news/topcon-healthcare-appoints-christian-odaker-as-chief-technology-officer/2482599/daily0.7https://crstodayeurope.com/news/lumibird-medical-rebrands-its-japanese-subsidiary/2482598/daily0.7https://crstodayeurope.com/news/oculis-announces-positive-phase-2-results-for-ocs-05-in-acute-optic-neuritis-as-a-potential-first-in-class-neuroprotective-therapy/2482597/daily0.7https://crstodayeurope.com/news/visiongift-announces-the-retirement-of-longtime-medical-director-mark-terry-md/2482595/daily0.7https://crstodayeurope.com/news/prevent-blindness-provides-free-glaucoma-resources-to-patients-care-partners-and-professionals/2482593/daily0.7https://crstodayeurope.com/news/new-museum-of-the-eye-exhibit-brings-images-to-life-for-the-visually-impaired-and-blind/2482592/daily0.7https://crstodayeurope.com/news/scientists-explore-regrowth-of-optic-nerves-as-potential-treatment-for-glaucoma/2482591/daily0.7https://crstodayeurope.com/news/glaukos-submits-new-drug-application-to-fda-for-epioxa/2482589/daily0.7https://crstodayeurope.com/news/national-eye-institute-study-revisits-role-of-annexin-v-biomarker-in-retinal-cell-degeneration/2482588/daily0.7https://crstodayeurope.com/news/aurion-announces-positive-topline-data-for-phase-12-trial-of-allogeneic-cell-therapy-for-corneal-edema-secondary-to-corneal-endothelial-dysfunction/2482584/daily0.7https://crstodayeurope.com/news/essilorluxottica-acquires-espansione-group-provider-of-noninvasive-ophthalmic-medical-devices/2482581/daily0.7https://crstodayeurope.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/daily0.7https://crstodayeurope.com/news/sepul-bio-annouces-dosage-of-first-participant-in-clinical-trial-using-ultevursen-for-retinitis-pigmentosa-treatment/2482578/daily0.7https://crstodayeurope.com/news/tenpoint-and-visus-complete-merger/2482576/daily0.7https://crstodayeurope.com/news/provectus-launches-visirose-company-to-commercialize-rose-bengal-pdat/2483756/daily0.7https://crstodayeurope.com/news/cellviva-appoints-three-ophthalmology-leaders-to-board-of-directors/2482577/daily0.7https://crstodayeurope.com/news/bausch-lomb-acquires-elios-vision-to-bolster-glaucoma-surgical-portfolio/2482575/daily0.7https://crstodayeurope.com/news/iantrek-announces-publication-highlighting-12-month-results-for-its-bio-interventional-uveoscleral-outflow-technology/2482574/daily0.7https://crstodayeurope.com/news/vialase-and-the-john-a-moran-eye-center-announce-research-partnership-to-accelerate-glaucoma-research-and-innovation/2482573/daily0.7https://crstodayeurope.com/news/arpa-h-announces-pioneering-investments-to-reverse-blindness/2482572/daily0.7https://crstodayeurope.com/news/the-centre-for-eye-and-vision-research-and-scope-health-partner-to-innovate-ocular-surface-disease-solutions/2482571/daily0.7https://crstodayeurope.com/news/onesight-essilorluxottica-foundation-partners-with-who-on-specs-2030-initiative-1/2482570/daily0.7https://crstodayeurope.com/news/nicox-announces-first-commercial-sale-of-zerviate-in-china-by-partner-ocumension/2482566/daily0.7https://crstodayeurope.com/news/galimedix-therapeutics-begins-phase-1-clinical-trial-of-oral-gal-101-for-neuroprotective-treatment/2482565/daily0.7https://crstodayeurope.com/news/ophthalmic-industry-veteran-scott-hunter-passes-away/2482564/daily0.7https://crstodayeurope.com/news/nicoxs-denali-phase-3-trial-of-ncx-470-fully-enrolled-in-china/2482561/daily0.7https://crstodayeurope.com/news/nidek-launches-np-t-preloaded-toric-iol-injection-system/2482560/daily0.7https://crstodayeurope.com/news/fda-clears-novoxels-tixel-for-the-treatment-of-meibomian-gland-dysfunction/2482559/daily0.7https://crstodayeurope.com/news/nih-led-science-team-defines-elements-of-brain-based-leading-cause-of-childhood-vision-loss/2482557/daily0.7https://crstodayeurope.com/news/johnson-johnson-appoints-shawn-millerick-president-vision-care-americas/2482556/daily0.7https://crstodayeurope.com/news/bostonsight-publishes-study-highlighting-prose-lens-utilization-for-drug-delivery/2482555/daily0.7https://crstodayeurope.com/news/melt-pharmaceuticals-announces-positive-phase-3-trial-results-for-melt-300-sedation-solution/2482552/daily0.7https://crstodayeurope.com/news/emmecell-announces-advancements-of-non-surgical-cell-therapy-for-corneal-edema/2482551/daily0.7https://crstodayeurope.com/news/alkeus-secures-rare-pediatric-disease-and-fast-track-fda-designations-for-gildeuretinol-in-stargardt-disease/2482549/daily0.7https://crstodayeurope.com/news/ophtec-receives-ce-mark-approval-for-artiplus-phakic-iol-for-presbyopia/2482548/daily0.7https://crstodayeurope.com/news/fda-accepts-aldeyras-nda-for-reproxalap-in-dry-eye-disease/2482547/daily0.7https://crstodayeurope.com/news/eyenovias-late-stage-pediatric-myopia-treatment-fails-to-meet-primary-endpoint/2482544/daily0.7https://crstodayeurope.com/news/myze-launches-the-daily-lid-wipe-to-elevate-daily-eye-care-partnering-with-leading-eye-health-experts/2482543/daily0.7https://crstodayeurope.com/news/atsena-therapeutics-and-nippon-shinyaku-enter-strategic-collaboration-for-atsn-101-advancement/2482542/daily0.7https://crstodayeurope.com/news/bausch-lombs-recycling-programs-collect-over-94-million-units-of-eye-care-waste-in-the-us/2482541/daily0.7https://crstodayeurope.com/news/kian-capital-and-rf-investment-partners-to-launch-us-visionmed-partners/2482540/daily0.7https://crstodayeurope.com/news/mediprint-ophthalmics-unveils-phase-2b-trial-results-for-drug-eluting-contact-lens-in-glaucoma-treatment/2482539/daily0.7https://crstodayeurope.com/news/harrow-launches-initiative-to-expand-access-and-affordability-for-eyecare-medications/2482538/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-names-namrata-saroj-as-chief-business-officer/2482536/daily0.7https://crstodayeurope.com/news/harrow-secures-medicare-part-d-market-access-for-vevye/2482535/daily0.7https://crstodayeurope.com/news/konan-medical-usa-launches-objectivefield-visual-field-analyzer/2482534/daily0.7https://crstodayeurope.com/news/alcon-unveils-precision7-one-week-contact-lens-with-activ-flo-technology/2482533/daily0.7https://crstodayeurope.com/news/harrow-partners-with-asembia-to-enhance-provider-and-patient-experience-through-nationwide-digital-services-and-hub-support-for-harrows-branded-eye-care-products/2482530/daily0.7https://crstodayeurope.com/news/cencora-advances-specialty-leadership-through-acquisition-of-retina-consultants-of-america/2482528/daily0.7https://crstodayeurope.com/news/tarsus-appoints-elizabeth-yeu-md-as-chief-medical-officer/2482527/daily0.7https://crstodayeurope.com/news/new-study-reveals-how-visual-clutter-alters-brains-processing-of-visual-information/2482522/daily0.7https://crstodayeurope.com/news/gensight-biologics-publishes-meta-analysis-on-efficacy-of-treatments-for-leber-hereditary-optic-neuropathy/2482521/daily0.7https://crstodayeurope.com/news/upenn-research-long-term-antiviral-use-is-key-to-ocular-shingles-treatment/2483755/daily0.7https://crstodayeurope.com/news/corxel-pharmaceuticals-and-lenz-therapeutics-announce-positive-phase-3-trial-results-for-presbyopia-eye-drop-lnz100-in-china/2482519/daily0.7https://crstodayeurope.com/news/epion-presents-survey-on-keratoconus-highlighting-urgent-need-for-accessible-treatments/2482518/daily0.7https://crstodayeurope.com/news/new-study-finds-higher-prevalence-of-glaucoma-and-related-vision-loss-than-previously-estimated/2482513/daily0.7https://crstodayeurope.com/news/study-of-alkeus-oral-gildeuretinol-demonstrate-significant-trend-in-slowing-ga-progression-and-visual-function-improvement/2482511/daily0.7https://crstodayeurope.com/news/stanford-university-study-finds-ovarian-cancer-drug-can-affect-the-eyes/2482510/daily0.7https://crstodayeurope.com/news/ocuphire-acquires-gene-therapy-company-opus-genetics/2482508/daily0.7https://crstodayeurope.com/news/cathleen-mccabe-md-appointed-strategic-medical-advisor-at-bausch-lomb/2482507/daily0.7https://crstodayeurope.com/news/study-slt-slows-glaucoma-progression-compared-to-topical-eye-drops/2482506/daily0.7https://crstodayeurope.com/news/life-biosciences-presents-new-data-on-novel-gene-therapy-at-aao/2482505/daily0.7https://crstodayeurope.com/news/ripple-therapeutics-announces-evaluation-and-licensing-agreements-with-glaukos/2482502/daily0.7https://crstodayeurope.com/news/johnson-johnson-to-showcase-tecnis-odyssey-iol-and-present-new-research-at-aao-2024/2482501/daily0.7https://crstodayeurope.com/news/spyglass-pharma-unveils-promising-18-month-data-from-first-in-human-study-of-glaucoma-drug-delivery-platform/2482500/daily0.7https://crstodayeurope.com/news/aao-home-oct-device-improves-care-for-amd-patients-reduces-costs-and-burden/2482499/daily0.7https://crstodayeurope.com/news/exponential-increase-in-anti-vegf-treatments-linked-to-higher-risk-of-complications-in-cataract-surgery-study-finds/2482498/daily0.7https://crstodayeurope.com/news/googles-diabetic-retinopathy-ai-model-licensed-for-use-in-india-and-thailand/2482497/daily0.7https://crstodayeurope.com/news/tarsus-launches-your-mitey-problem-the-first-direct-to-consumer-tv-campaign-for-xdemvy-lotilaner-ophthalmic-solution-025/2483754/daily0.7https://crstodayeurope.com/news/eye-health-america-and-versea-ophthalmics-form-preferred-supply-partnership/2482496/daily0.7https://crstodayeurope.com/news/glaukos-announces-positive-phase-3-results-for-epioxa-corneal-cross-linking-therapy/2482495/daily0.7https://crstodayeurope.com/news/ikerian-and-retinai-secure-8m-financing-to-drive-ai-healthcare-innovation/2482494/daily0.7https://crstodayeurope.com/news/bausch-lomb-announces-new-data-and-events-at-the-2024-aao-annual-meeting-in-chicago/2482493/daily0.7https://crstodayeurope.com/news/haag-streit-to-host-biometry-focus-month-2024-with-weekly-webinars-in-november/2482492/daily0.7https://crstodayeurope.com/news/ocular-therapeutix-announces-accelerated-timelines-for-sol-1-registrational-trial-of-axpaxli-in-wet-amd/2482490/daily0.7https://crstodayeurope.com/news/alcon-to-showcase-latest-innovations-at-aao-2024-annual-meeting/2482489/daily0.7https://crstodayeurope.com/news/centricity-vision-unveils-enhancements-to-zeptolink-iol-positioning-system-at-aao-2024/2482487/daily0.7https://crstodayeurope.com/news/heidelberg-engineering-receives-fda-clearance-for-spectralis-flex-module-for-supine-imaging/2482486/daily0.7https://crstodayeurope.com/news/casexglobal-lauches-first-ai-powered-site-management-organization/2482484/daily0.7https://crstodayeurope.com/news/glaukos-to-showcase-technologies-at-2024-aao-annual-meeting-in-chicago/2482483/daily0.7https://crstodayeurope.com/news/bausch-lomb-announces-fda-approval-of-envista-envy-full-range-of-vision-iol/2482482/daily0.7https://crstodayeurope.com/news/retinalyze-launches-advanced-glaucoma-progression-ai/2482480/daily0.7https://crstodayeurope.com/news/zeiss-to-showcase-new-digital-ai-tools-and-surgical-solutions-at-aao/2482479/daily0.7https://crstodayeurope.com/news/beyeonics-vision-launches-beyeonics-one-featuring-infrared-technology/2482478/daily0.7https://crstodayeurope.com/news/melt-pharmaceuticals-announces-completion-of-patient-dosing-in-phase-3-study-of-melt-300-for-procedural-sedation/2482477/daily0.7https://crstodayeurope.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/daily0.7https://crstodayeurope.com/news/orasis-secures-78-million-to-support-commercial-launch-of-presbyopia-eye-drops-qlosi/2482474/daily0.7https://crstodayeurope.com/news/marinomed-biotech-reports-promising-phase-2-results-for-tacrosolv-eye-drops-in-treating-allergic-rhinoconjunctivitis/2482473/daily0.7https://crstodayeurope.com/news/nextgen-healthcare-launches-ai-powered-ambient-listening-solution-for-ophthalmologists-and-optometrists/2482472/daily0.7https://crstodayeurope.com/news/cure-blindness-project-unveils-global-expansion-plan-on-world-sight-day/2482471/daily0.7https://crstodayeurope.com/news/new-study-unveils-how-immune-cells-defend-the-eye-against-inflammation/2482470/daily0.7https://crstodayeurope.com/news/aldeyra-resubmits-nda-for-topical-ocular-reproxalap-for-dry-eye-disease/2482469/daily0.7https://crstodayeurope.com/news/after-shortage-harrow-announces-relaunch-of-triesence/2482468/daily0.7https://crstodayeurope.com/news/rayner-announces-first-rayone-galaxy-implantations-in-the-us/2482467/daily0.7https://crstodayeurope.com/news/novaliq-and-laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye/2482466/daily0.7https://crstodayeurope.com/news/bausch-lomb-launches-opal-digital-marketplace-in-the-us/2482465/daily0.7https://crstodayeurope.com/news/maximeyescom-ophthalmology-ehr-integrates-with-aao-iris-registry/2482464/daily0.7https://crstodayeurope.com/news/ocuphire-publishes-phase-3-trial-results-of-ryzumvi-for-pharmacologically-induced-mydriasis-1/2482463/daily0.7https://crstodayeurope.com/news/jjs-tecnis-odyssey-pc-iol-now-fully-commercially-available/2482462/daily0.7https://crstodayeurope.com/news/sifi-secures-european-patent-for-treatment-of-acanthamoeba-and-fungal-keratitis-set-to-launch-akantior-in-germany/2483753/daily0.7https://crstodayeurope.com/news/andreas-pecher-to-succeed-dr-karl-lamprecht-as-president-and-ceo-of-carl-zeiss-ag/2482461/daily0.7https://crstodayeurope.com/news/hoya-vision-care-announces-8-year-study-on-miyosmart-myopia-control-lenses/2483752/daily0.7https://crstodayeurope.com/news/eyenovia-launches-clobetasol-for-postoperative-ocular-surgery-pain-and-inflammation/2482460/daily0.7https://crstodayeurope.com/news/zeiss-launches-micor-700-lens-extraction-device/2482459/daily0.7https://crstodayeurope.com/news/aurion-biotech-launches-vyznova-in-japan-the-first-cell-therapy-for-corneal-endothelial-disease/2482458/daily0.7https://crstodayeurope.com/news/hoya-highlights-the-impact-rural-vs-urban-living-environments-may-have-on-myopia-in-young-children/2482457/daily0.7https://crstodayeurope.com/news/neuro-optometric-rehabilitation-association-appoints-barbara-barclay-as-new-executive-director/2482455/daily0.7https://crstodayeurope.com/news/aaof-and-meta-reality-labs-launch-15-million-open-science-initiative-to-study-myopia-and-visual-experience/2482454/daily0.7https://crstodayeurope.com/news/lumibird-unveils-omnicad-imaging-platform-for-ocular-surface-disease/2482453/daily0.7https://crstodayeurope.com/news/staar-opens-new-experience-center-to-meet-growing-surgeon-demand/2482452/daily0.7https://crstodayeurope.com/news/nicox-and-glaukos-sign-global-licensing-deal-for-glaucoma-drug-candidate/2482451/daily0.7https://crstodayeurope.com/news/nih-study-confirms-effectiveness-of-eyelid-surgeries-for-treating-trachomatous-trichiasis/2483751/daily0.7https://crstodayeurope.com/news/oculis-and-euretina-announce-winner-of-inaugural-ramin-tadayoni-award/2482449/daily0.7https://crstodayeurope.com/news/visionix-usa-introduces-groundbreaking-topography-module-for-optovue-solix-oct-systems/2482448/daily0.7https://crstodayeurope.com/news/nicox-announces-approval-of-zerviate-in-china-for-allergic-conjunctivitis/2483750/daily0.7https://crstodayeurope.com/news/microsurgical-technology-mst-announces-global-partnership-with-vista-ophthalmics/2482446/daily0.7https://crstodayeurope.com/news/alkeus-pharmaceuticals-announces-positive-results-from-saga-study-of-gildeuretinol-acetate-in-ga-patients-3/2482445/daily0.7https://crstodayeurope.com/news/ripple-therapeutics-partners-with-abbvie-to-develop-intracameral-implant-for-glaucoma/2482444/daily0.7https://crstodayeurope.com/news/new-study-on-ai-driven-solutions-for-diabetic-eye-disease-testing-in-underserved-populations-published/2482441/daily0.7https://crstodayeurope.com/news/auras-phase-2-study-of-bel-sar-to-treat-early-stage-choroidal-melanoma-presented/2483749/daily0.7https://crstodayeurope.com/news/topcon-receives-fda-clearance-for-octa-on-the-maestro2-system/2482439/daily0.7https://crstodayeurope.com/news/zeiss-to-showcase-3d-visualization-and-ai-innovations-at-euretina-2024/2482438/daily0.7https://crstodayeurope.com/news/iantrek-publishes-clinical-results-of-uveoscleral-outflow-technology-for-open-angle-glaucoma/2482437/daily0.7https://crstodayeurope.com/news/icare-launches-st500-slit-lamp-based-tonometry/2482436/daily0.7https://crstodayeurope.com/news/hilco-vision-appoints-girisha-chandraraj-as-new-ceo/2482435/daily0.7https://crstodayeurope.com/news/viridian-announces-positive-topline-results-from-phase-3-trial-of-veligrotug-for-thyroid-eye-disease/2482434/daily0.7https://crstodayeurope.com/news/alcon-unveils-innovations-at-escrs-including-smartcataract-dx-and-ngenuity-15/2482433/daily0.7https://crstodayeurope.com/news/ocuphire-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-075-for-presbyopia/2482432/daily0.7https://crstodayeurope.com/news/aurion-biotech-to-present-at-escrs-and-ophthalmology-futures-european-forum/2482430/daily0.7https://crstodayeurope.com/news/opthea-announces-executive-leadership-changes-and-senior-hires/2482429/daily0.7https://crstodayeurope.com/news/novasight-publishes-study-on-curesight-digital-eye-tracking-device-for-amblyopia/2483748/daily0.7https://crstodayeurope.com/news/medicel-unveils-environmentally-friendly-terralution-range-at-escrs/2482428/daily0.7https://crstodayeurope.com/news/ciliatech-to-present-36-month-follow-up-results-on-intercil-uveal-spacer-at-ophthalmology-futures-european-forum/2482427/daily0.7https://crstodayeurope.com/news/alcon-announces-new-cataract-surgery-outcomes-data-hosts-educational-program-at-escrs/2482426/daily0.7https://crstodayeurope.com/news/oculus-unveils-pentacam-cornea-oct-at-escrs-2024/2482425/daily0.7https://crstodayeurope.com/news/pulsesight-therapeutics-establishes-international-scientific-and-clinical-advisory-board/2482424/daily0.7https://crstodayeurope.com/news/vialase-to-present-glaucoma-treatment-data-at-escrs-2024-in-barcelona/2482423/daily0.7https://crstodayeurope.com/news/samsara-vision-promotes-jason-herod-to-chief-commercial-officer/2482421/daily0.7https://crstodayeurope.com/news/bvi-to-unveil-serenity-and-serenity-toric-premium-monofocal-iols-at-escrs/2482420/daily0.7https://crstodayeurope.com/news/bausch-lomb-announces-new-scientific-data-educational-events-at-escrs/2482419/daily0.7https://crstodayeurope.com/news/haag-streit-unveils-metis-ophthalmic-microscope-system/2482418/daily0.7https://crstodayeurope.com/news/avanzanite-bioscience-secures-european-commission-approval-for-akantior-first-treatment-for-acanthamoeba-keratitis/2482417/daily0.7https://crstodayeurope.com/news/oculus-debuts-dual-testing-functionality-on-easyfield-vr-for-enhanced-visual-field-assessment/2482416/daily0.7https://crstodayeurope.com/news/zeiss-to-unveil-several-new-innovations-at-escrs-2024/2482415/daily0.7https://crstodayeurope.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/daily0.7https://crstodayeurope.com/news/injectsense-completes-first-successful-human-implant-of-ultraminiature-intraocular-pressure-sensor/2482413/daily0.7https://crstodayeurope.com/news/rayner-announces-launch-of-rayone-galaxy-first-ai-designed-spiral-iol/2482411/daily0.7https://crstodayeurope.com/news/yale-study-uncovers-how-brain-wiring-begins-before-birth/2482409/daily0.7https://crstodayeurope.com/news/study-targets-early-signs-of-vision-loss-in-diabetic-patients/2482408/daily0.7https://crstodayeurope.com/news/ftc-backs-fda-draft-guidance-on-interchangeable-biosimilar-drugs-aims-to-boost-patient-access-to-affordable-medication/2482406/daily0.7https://crstodayeurope.com/news/ocutech-announces-limited-release-of-sidesight-ultrasonic-sensor-device-for-homonymous-hemianopia/2482405/daily0.7https://crstodayeurope.com/news/inaugural-eyecelerator-innovation-award-presented-to-regeneron-executives/2482404/daily0.7https://crstodayeurope.com/news/opus-genetics-receives-fda-rare-pediatric-disease-designation-for-gene-therapy-opgx-lca5/2482403/daily0.7https://crstodayeurope.com/news/visiox-pharmaceuticals-merges-with-ocuvex-therapeutics/2482402/daily0.7https://crstodayeurope.com/news/orbis-launches-ai-led-diabetic-retinopathy-screening-project-in-vietnam/2482401/daily0.7https://crstodayeurope.com/news/lupin-receives-tentative-fda-approval-for-generic-version-of-lumify/2482400/daily0.7https://crstodayeurope.com/news/abigail-markward-named-executive-director-of-asoa/2482399/daily0.7https://crstodayeurope.com/news/lenz-therapeutics-submits-new-drug-application-for-lnz100-eye-drop-for-presbyopia-treatment/2482397/daily0.7https://crstodayeurope.com/news/ocumension-therapeutics-secures-deal-with-alcon-to-expand-dry-eye-treatment-portfolio-in-china/2482395/daily0.7https://crstodayeurope.com/news/contact-lens-institute-opens-nominations-for-second-annual-culture-awards/2482394/daily0.7https://crstodayeurope.com/news/bausch-lomb-publishes-teneo-excimer-laser-clinical-trial-results/2482393/daily0.7https://crstodayeurope.com/news/nih-study-reveals-significant-gaps-in-medicaid-coverage-for-adult-vision-care/2482392/daily0.7https://crstodayeurope.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap/2482391/daily0.7https://crstodayeurope.com/news/lensars-ally-adaptive-cataract-treatment-system-approved-in-europe/2482390/daily0.7https://crstodayeurope.com/news/lumithera-announces-first-cpt-code-to-report-photobiomodulation-therapy-in-retinal-disease/2482389/daily0.7https://crstodayeurope.com/news/annexon-provides-update-on-archer-ii-global-registrational-program-in-geographic-atrophy/2482386/daily0.7https://crstodayeurope.com/news/eyedaptic-unveils-eye6-with-ivy-ai-powered-visual-assistant-for-people-with-retinal-disorders/2482385/daily0.7https://crstodayeurope.com/news/ascrs-launches-summit-designed-to-enhance-refractive-cataract-surgery-practices/2482384/daily0.7https://crstodayeurope.com/news/novaliq-receives-positive-chmp-opinion-for-vevizye-in-dry-eye-disease/2482383/daily0.7https://crstodayeurope.com/news/ocular-therapeutixs-axpaxli-phase-3-sol-r-wet-amd-study-begins-enrollment/2482382/daily0.7https://crstodayeurope.com/news/topcons-is-6500-ophthalmic-instrument-stand-launched/2482381/daily0.7https://crstodayeurope.com/news/roches-vabysmo-approved-in-europe-for-treatment-of-rvo/2482379/daily0.7https://crstodayeurope.com/news/vialase-laser-receives-ce-mark-approval-to-treat-glaucoma/2482378/daily0.7https://crstodayeurope.com/news/alcon-research-institutes-executive-committee-to-be-chaired-by-dr-allen-c-ho/2483747/daily0.7https://crstodayeurope.com/news/clearside-and-arctic-vision-report-data-from-trial-of-arcatis-to-treat-uveitic-macular-edema-in-china/2482380/daily0.7https://crstodayeurope.com/news/ohsu-researchers-discover-link-between-proteins-in-tears-pain-after-eye-surgery/2482376/daily0.7https://crstodayeurope.com/news/nicox-announces-recruitment-of-last-patient-in-us-in-denali-phase-3-trial-of-ncx-470/2482375/daily0.7https://crstodayeurope.com/news/nova-eye-to-feature-several-presentations-and-posters-related-to-itrack-canaloplasty-at-2024-escrs-annual-congress/2482374/daily0.7https://crstodayeurope.com/news/spryte-medical-receives-breakthrough-device-designation-from-fda-for-neuro-optical-coherence-tomography-noct-technology/2482373/daily0.7https://crstodayeurope.com/news/johnson-johnson-invests-in-refractive-technology-start-up-teclens/2482372/daily0.7https://crstodayeurope.com/news/oertli-instrumente-ag-achieves-milestone-with-fda-510k-clearance-for-faros-surgical-system/2482371/daily0.7https://crstodayeurope.com/news/osheru-secures-47-million-seed-funding-to-advance-ziplyft-device-for-blepharoplasty-surgery/2482370/daily0.7https://crstodayeurope.com/news/abbvie-launches-refresh-tears-pf-and-refresh-relieva-pf-xtra/2482369/daily0.7https://crstodayeurope.com/news/bausch-lomb-acquires-diagnostic-company-trukera-medical/2482368/daily0.7https://crstodayeurope.com/news/topcon-and-orbis-international-partner-to-expand-diabetic-retinopathy-screening-in-rwanda/2482367/daily0.7https://crstodayeurope.com/news/richard-rosen-md-receives-founders-award-from-asrs/2482366/daily0.7https://crstodayeurope.com/news/essilorluxottica-acquires-majority-stake-in-heidelberg-engineering/2482362/daily0.7https://crstodayeurope.com/news/opthea-welcomes-international-retina-thought-leaders-to-its-medical-advisory-board/2482361/daily0.7https://crstodayeurope.com/news/pulsemedica-raises-12-million-to-advance-eye-floater-imaging-and-treatment-technology/2482360/daily0.7https://crstodayeurope.com/news/heidelberg-engineering-introduces-faster-oct-angiography-with-spectralis-shift-technology/2482359/daily0.7https://crstodayeurope.com/news/perry-j-sternberg-joins-sydnexis-as-chief-executive-officer/2482358/daily0.7https://crstodayeurope.com/news/nicox-appoints-new-chair-of-the-board-and-director/2482357/daily0.7https://crstodayeurope.com/news/claes-h-dohlman-md-cornea-research-pioneer-and-visionary-passes-away-at-101/2482356/daily0.7https://crstodayeurope.com/news/ocucell-announces-funding-from-altruvision-and-leadership-changes/2482354/daily0.7https://crstodayeurope.com/news/global-perspectives-on-childhood-myopia-addressing-the-rising-epidemic/2483746/daily0.7https://crstodayeurope.com/news/okyo-pharma-to-initiate-neuropathic-corneal-pain-trial-for-ok-101/2482353/daily0.7https://crstodayeurope.com/news/ior-partners-appoints-lance-j-kugler-md-to-the-role-of-strategic-advisory-board-chairman/2482351/daily0.7https://crstodayeurope.com/news/harrow-enters-into-340b-prime-vendor-program-contract-with-apexus-for-iheezo/2482349/daily0.7https://crstodayeurope.com/news/bl-shares-dry-eye-survey-results-and-launches-awareness-campaign/2482346/daily0.7https://crstodayeurope.com/news/eyesouth-partners-unveils-clinical-research-division/2482345/daily0.7https://crstodayeurope.com/news/cdrh-expands-tap-program-to-include-ophthalmic-devices/2482344/daily0.7https://crstodayeurope.com/news/genentechs-vabysmo-prefilled-syringe-approved-by-fda-for-amd-dme-and-rvo/2482342/daily0.7https://crstodayeurope.com/news/beacon-therapeutics-raises-funds-to-advance-development-of-its-ophthalmic-gene-therapies/2482341/daily0.7https://crstodayeurope.com/news/cms-j-code-for-glaukos-idose-tr-becomes-active/2482340/daily0.7https://crstodayeurope.com/news/nurexones-exosome-based-exopten-therapy-studied-to-treat-glaucoma/2482339/daily0.7https://crstodayeurope.com/news/alcon-completes-acquisition-of-belkin-vision/2482338/daily0.7https://crstodayeurope.com/news/roches-vabysmo-gets-chmp-recommendation-for-rvo-indication/2482337/daily0.7https://crstodayeurope.com/news/nei-funded-study-reveals-neural-mechanism-of-encoding-familiar-faces/2482335/daily0.7https://crstodayeurope.com/news/karen-petrou-appointed-board-chair-of-the-foundation-fighting-blindness/2482334/daily0.7https://crstodayeurope.com/news/fda-grants-denovo-classification-to-balance-ophthalmics-fysxtm-ocular-pressure-adjusting-pump/2482333/daily0.7https://crstodayeurope.com/news/rayner-closes-recruitment-for-ide-for-rayone-emv-toric-iols/2482332/daily0.7https://crstodayeurope.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/daily0.7https://crstodayeurope.com/news/ikerian-receives-eu-mdr-certificate-for-four-devices-its-ophthalmology-data-platform-and-ai-models/2482328/daily0.7https://crstodayeurope.com/news/bausch-lomb-announces-presentation-of-new-data-at-the-european-dry-eye-society-2024-congress/2483745/daily0.7https://crstodayeurope.com/news/aurion-biotech-ceo-greg-kunst-named-ernst-young-2024-entrepreneur-of-the-year-mountain-west-region/2483744/daily0.7https://crstodayeurope.com/news/2024-kavli-prize-in-neuroscience-awarded-for-the-discovery-of-face-areas-in-the-brain/2482322/daily0.7https://crstodayeurope.com/news/eyecare-partners-names-new-members-to-executive-leadership-team/2482321/daily0.7https://crstodayeurope.com/news/opus-genetics-receives-17-million-in-funding-from-the-foundation-fighting-blindness-to-support-two-preclinical-programs/2482320/daily0.7https://crstodayeurope.com/news/oertli-instrumente-wins-the-swiss-medtech-award/2482318/daily0.7https://crstodayeurope.com/news/skye-fails-phase-2-glaucoma-trial-shifts-focus-to-obesity/2482317/daily0.7https://crstodayeurope.com/news/bausch-lomb-introduces-infuse-for-astigmatism-silicone-hydrogel-daily-disposable-contact-lenses/2482316/daily0.7https://crstodayeurope.com/news/nidek-receives-ce-mark-approval-for-preloaded-iol-injection-system/2482315/daily0.7https://crstodayeurope.com/news/geoff-tabin-md-co-founder-of-global-ngo-hcp-cureblindness-steps-into-new-role/2482314/daily0.7https://crstodayeurope.com/news/galimedix-therapeutics-establishes-scientific-advisory-board-in-advance-of-phase-2-study-of-gal-101-for-dry-amd/2482313/daily0.7https://crstodayeurope.com/news/melt-pharmaceuticals-doses-first-patient-in-pivotal-phase-3-program-of-melt-300-opioid-free-sedation/2482312/daily0.7https://crstodayeurope.com/news/rayner-announces-new-appointments-to-management-board/2482311/daily0.7https://crstodayeurope.com/news/eversight-partners-with-lightoptech-to-improve-imaging-modalities-for-eye-tissues/2482310/daily0.7https://crstodayeurope.com/news/harrow-announces-52-week-data-from-vevye-essence-2-open-label-extension-study/2482309/daily0.7https://crstodayeurope.com/news/nominations-now-being-accepted-for-neuro-optometric-rehabilitation-association-awards/2482308/daily0.7https://crstodayeurope.com/news/azura-ophthalmics-enrolls-first-patient-in-phase-3-clinical-trial-for-azr-md-001-in-patients-with-mgd/2482307/daily0.7https://crstodayeurope.com/news/aurion-biotech-completes-enrollment-in-phase-12-clinical-trial-of-allogeneic-cell-therapy-candidate/2482306/daily0.7https://crstodayeurope.com/news/bausch-lomb-launches-blink-nutritears-nutritional-supplement-for-dry-eyes-in-the-us/2482305/daily0.7https://crstodayeurope.com/news/nidek-launches-the-rs-1-glauvas-optical-coherence-tomography/2482304/daily0.7https://crstodayeurope.com/news/biotissue-introduces-cam360-amniograft-regenerative-therapy-for-dry-eye-and-ocular-surface-disorders/2482303/daily0.7https://crstodayeurope.com/news/lambdavision-closing-of-seed-round-to-advance-artificial-retina-preclinical-studies/2482302/daily0.7https://crstodayeurope.com/news/nordic-pharma-launches-lacrifill-canalicular-gel-for-dry-eye/2482301/daily0.7https://crstodayeurope.com/news/sightpath-medical-acquires-lasik-services-provider-pennvista/2482300/daily0.7https://crstodayeurope.com/news/zeiss-announces-oct-enhancements-to-cirrus-6000/2482299/daily0.7https://crstodayeurope.com/news/quantel-medical-launches-pocket-iii-handheld-pachymeter/2482298/daily0.7https://crstodayeurope.com/news/dopavision-announces-topline-results-in-clinical-trial-of-targeted-photobiomodulation-approach-for-progressive-myopia/2482295/daily0.7https://crstodayeurope.com/news/bausch-lomb-receives-health-canada-approval-for-envista-envy-full-visual-range-iol/2482293/daily0.7https://crstodayeurope.com/news/latinos-en-optometry-launches-redesigned-website-and-new-domain-name/2482291/daily0.7https://crstodayeurope.com/news/new-world-medical-receives-510k-clearance-for-kdb-glide-expanded-indication-for-reduction-of-iop/2482290/daily0.7https://crstodayeurope.com/news/heidelberg-engineering-presents-xtreme-research-award/2482287/daily0.7